News
4 Oct 2021
Thermo Fisher Scientific Opens cGMP Plasmid DNA Manufacturing Facility in Carlsbad, California
Responding to critical market capacity constraints, Thermo Fisher announces the official opening of new 67,000 sqft cGMP plasmid DNA manufacturing facility in Carlsbad, CA. This site expands clinical and commercial capabilities for cGMP plasmid DNA used as a critical raw material to develop and manufacture cell and gene-based therapies in addition to capabilities to produce large-scale plasmid DNA as a primary drug substance for DNA therapies.
Accelerate development of plasmid-based medicines and vaccines
Mentioned Companies
Thermo Fisher Scientific Inc.
Related News
-
Sponsored Content CPhI Webinar: Early multi-functional approach is the best way to incorporate patient centricity into drug formulations
The concept of patient centricity has many nuances, and designing dosage forms needs to be underpinned by a multi-functional perspective utilised as early as possible, say experts -
Sponsored Content Biocatalysis: An Indispensable Tool for Synthesis of Active Pharmaceutical Ingredients
Biocatalytic processing offers a wealth of advantages and should be evaluated during early-stage drug development for its potential to improve yields, increase efficiency, and support greener manufacturing. -
Sponsored Content CPhI Webinar: Develop ODTs in a FLASH with UltraBurst™ - Watch On Demand
Catch up on the latest trends and developments in orally disintegrating tablet (ODT) formulation development -
Sponsored Content IFF Pharma Solutions: Paving the Way for Superior Suspensions
Shawn Branning, Global Strategic Marketing Manager at IFF – Pharma Solutions -
Sponsored Content CPhI Monthly Podcast: Selecting the Right CDMO Outsourcing Partner
Sponsors within the biopharmaceutical industry are increasingly turning to outsourcing for several reasons; remaining competitive and flexible within a quickly evolving sector, gaining access to manufacturing capacity and state-of-the-art equipment and... -
Sponsored Content Clinical & Commercial Drug Product Manufacturing: Outsourcing Advice from a CDMO
Taking a sterile drug product from clinical to commercial scale brings unique challenges. In this article, LLS Health investigates ways to mitigate scale-up challenges and achieve success. -
Sponsored Content Sterile manufacturing Annex 1 amendments: what, why and how explained
In January 2020 the European Commission published some proposed significant revisions to Annex 1, the EU’s good manufacturing practice (GMP) guide for the manufacture of sterile products. In the following three-month consultation period, affected... -
Sponsored Content Learning Lab: How COVID-19 is Redefining Drug Development and Manufacturing
Watch this Learning Lab video presented by Chris McPherson, Principal Scientist, DS Manufacturing, Samsung Biologics, which details how CDMOs have reacted to the challenging ‘Black Swan’ event that is the COVID-19 pandemic by initiatin...
Position your company at the heart of the global Pharma industry with a CPhI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPhI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance